Abstract
The commonest renal tumor in adults is that arising from the cells of renal parenchyma. These cancers were described by Grawitz (1883), who named them hypernephromas upon the supposition that they might arise from nests of adrenal tissue in the kidney. The names ‘hypernephroma’ and ‘Grawitz tumor’ are obsolete, and renal carcinoma (or renal cell carcinoma) is the most appropriate term, since the tumors arise from the secretory cells of the renal tubular epithelium. Renal carcinoma is not a common disease; its incidence is about 7.5 cases per 100,000 population. In the United States there are about 7000 deaths from this tumor each year (American Cancer Society 1973): this represents 2.3% of male cancer deaths and 1.6% of cancer deaths in women.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alberto P, Senn HJ (1974) Hormonal therapy of renal carcinoma alone and in association with cytostatic drugs. Cancer 33:1226–1229
Al-Sarraf M (1979) The clinical trial of tamoxifen in patients with advanced renal cell cancer. A Southwest Oncology Group study. Proc Am Soc Clin Oncol 20:378, C-360
American Cancer Society (1973) Cancer facts and figures. New York: American Cancer Society
Bloom HJG (1973) Hormone-induced and spontaneous regression of metastatic renal cancer. Cancer 32: 1066–1071
Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405–410
Bukowski RM, Groppe C, Reimer R, Weick J, Hewlett JS (1979) Immunotherapy (IT)of metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 20:402, C-457
Carter RL (1968) The pathology of renal cancer. JAMA 204:221–222
Carter SK, Wasserman TH (1975) The chemotherapy of urologic cancer. Cancer 36:729–747
Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S, Jacobs SC, Brown RS (1979) Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 310:592–595
Concolino G, Marocchi A, Conti C, Tenaglia R, Di Silverio F, Bracci U (1978) Human renal cell carcinoma as a hormone-dependent tumor. Cancer Res 38:4340–4344
Currie VE, Kempin SJ, Sykes MP, Young CW (1979) Clinical studies of 2,4-diamino-5-(3’4’-dichlorophenyl)-6-methylpyrimidine (metoprine) with and without leucovorin. Proc Am Assoc Cancer Res 20:112,454
Davis TE, Manalo FB (1978) Combination chemotherapy of advanced renal cell cancer with CCNU and vinblastine. Proc Am Soc Clin Oncol 19:316, C-39
Everson TC, Cole WH (1966) Spontaneous regression of cancer. Saunders, Philadelphia London
Faulconer RJ, Rosato FE, Wright GL, Schellhammer P (1978) Detection and isolation of antigens associated with renal cell carcinoma. Proc Am Soc Clin Oncol 19:308, C-8
Fuks JZ, Van Echo DA, Aisner J, Kravitz S, Wiernik PH (1980) A Phase II trial of 4’-(9-acrindinyl-amino)-methanesulfon-m-anisidine (AMSA) in patients with renal cell carcinoma (RCC) and refractory small cell carcinoma of the lung (SCCL). Proc Am Soc Clin Oncol 21:477, C-622
Ghose T, Tai J, Blair AH, Belitsky P, Aquino J, Norvell ST (1978) Antitumor antibodies as carriers of radionucleidesand cytotoxic drugs. Proc Am Assoc Cancer Res 19:236,942
Glick J, Wein A, Negendank W, Harris D, Brodovsky H, Padavic K, Torri S (1979) Tamoxifen in metastatic prostate and renal cancer. Proc Am Soc Clin Oncol 20:311, C-81
Grawitz P (1883) Die sogenannten Lipomas der Niere. Virchow Arch [Pathol Anat] 93:39–63
Hahn RG (1977) Megace, VP-16, Cytoxan and galactitol. Phase II treatment trials in advanced renal cell cancer. Proc Am Soc Clin Oncol 18:332, C-262
Hahn RG, Temkin NR, Savlov ED, Perlia C, Wampler GL, Horton J, Marsh J, Carbone PP (1978) Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer. Cancer Treat Rep 62:1093–1095
Hrushesky WJ (1977) What’s old and new in advanced renal cell carcinoma. Proc Am Soc Clin Oncol 18: 318, C-206
Ishmael DR, Bottomley R, Geyer J (1980) Effect of nephrectomy on eventual response to chemotherapy in renal cell carcinoma. Proc Am Soc Clin Oncol 21:429, C-439
Ishmael DR, Bottomley RH, Hoge AF (1976) Treatment of renal cell adenocarcinoma (hypernephroma) with Depo-Provera and combination chemoimmunotherapy. Proc Am Soc Clin Oncol 17:265, C-113
Ishmael DR, Burpo LJ, Bottomley RH (1978) Combined therapy of advanced hypernephroma with medroxyprogesterone, BCG, adriamycin and vincristine. Proc Am Soc Clin Oncol 19:407, C-403
Katakkar SB, Franks CR (1978) Chemo-hormonal therapy for metastatic renal cell carcinoma with adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate. Cancer Treat Rep 62: 1379–1380
Kato T, Nemoto R, Mori H, Kumagai I (1979) Microencapsulated mitomycin-C therapy in renal cell carcinoma. Lancet II: 479–480
Kirkman H (1959) Estrogen-induced tumors of the kidney in the Syrian hamster. Natl Cancer Inst Mongr 1: 1–37
Kirulata G, Morales A, Lott S (1975) Response of renal adenocarcinoma to cyclophosphamide. Urology 6: 557–558
Knight WA, Livingston RB, Fabian C, Costanzi J (1979) Methyl-glyoxal bis-guanylhydrazone (methyl-GAG, MGBG) in advanced human malignancy. Proc Am Soc Clin Oncol 20:319, C-115
Knight WA, Livingston RB, Fabian C, Costanzi J (1980) Methyl-glyoxal bis-guanulhydrazone (methyl-GAG, MGBG) in advanced renal carcinoma. Proc Am Soc Clin Oncol 21: 367, C-190
Kradjian JM, Bennington JL (1964) Renal carcinoma recurrent 31 years after nephrectomy. Arch Surg 90:192–195
Levi J A, Dalley D, Aroney R (1980) A comparative trial of the combination vinblastine (V), methotrexate (A) and bleomycin (B) with and without tamoxifen (T) for metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 21:426, C-425
Li JJ, Li SA, Gonzales R(1979) Specific hormone binding in human renal carcinoma and kidney. Proc Am Assoc Cancer Res 20: 273, 1107
Lokich JL, Harrison JH (1975) Renal cell carcinoma: natural history and chemotherapeutic experience. J Urol 114: 371–374
Luderer RC, Opipari MI, Perrotta AL (1978) Treatment of metastatic renal cell carcinoma: Review of experience and world literature. Journal of the American Osteopathic Association 77: 590–603
McPherson TA, Tan YH (1979) Phase I study of human fibroblast interferon (FI) in human malignancy. Proc Am Soc Clin Oncol 20:378, C-361
Middleton RG (1967) Surgery for metastatic renal cell carcinoma. J Urol 97:973–977
Miller CF, Blom J (1980) Adjuvant chemotherapy of renal cell carcinoma using a combination of bleomycin (BLM) and lomustine (CCNU). Proc Am Soc Clin Oncol 21:362, C-171
Mittelman A, Albert DJ, Murphy GP (1973) Lomustine treatment of metastatic renal cell carcinoma. JAMA 225: 32–35
Papac R, Luikhart S, Kirkwood J (1980) High-dose tamoxifen in patients with advanced renal cell cancer and malignant melanoma. Proc Am Soc Clin Oncol 21: 358, C-155
Papac RJ, Ross AS, Levy A (1977) Renal cell carcinoma: analysis of 31 cases with assessment of endocrine therapy. Am J Med Sci 274: 281–289
Prager MD, Peters PC, Baechtel FS, Brown G (1980) Specific immunotherapy of metastatic human renal cell carcinoma: preliminary results. Proc Am Assoc Cancer Res 21:213,856
Price LA, Goldie JH, Hill BT (1975) Methodichlorophen as anti-tumour drug. Br Med J i: 20–21
Prout GR (1973) The kidney and ureter. In: Holland JF, Frei E (eds) Cancer medicine. Lea & Febiger, Philadelphia, pp 1655–1669
Ramming KP, deKernion JB (1977) Immune RNA therapy for renal cell carcinoma: Survival and immunologic monitoring. Ann Surg 186:459–466
Ramming KP, Gupta RK, deKernion JB (1977) Detection of antibodies to tumor associated antigens in patients with hypernephroma. Proc Amer Soc Clin Oncol 18:319, C-211
Ramming KP, Gupta RK, deKernion JB (1979) Induction of antibody to human renal cell cancer in vivo by injections of xenogeneic immune RNA. Proc Am Assoc Cancer Res 20:215, 872
Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101:297–301
Rodriguez LH, Johnson DE (1978) Clinical trial of cisplatinum (NSC 119875) in metastatic renal cell carcinoma. Urology 11:344–346
Samuels ML, Sullivan P, Howe CD (1968) Medroxyprogesterone acetate in the treatment of renal cell carcinoma (hypernephroma). Cancer 22:525–532
Spiers ASD, Allar M (1979) Beneficial effects of concurrent androgen treatment during cytotoxic chemotherapy. Proc Am Soc Clin Oncol 20:295, C-8
Talley RW (1973) Chemotherapy of adenocarcinoma of the kidney. Cancer 32: 1062–1065
Todd RF, Garnick MB, Canellos GP (1980) Chemotherapy of advanced renal adenocarcinoma with methyl-glyoxal-bis-guanylhydrazone (methyl-GAG). Proc Am Soc Clin Oncol 21:340, C-85
Wagle DG, Murphy GP (1971) Hormonal therapy in advanced renal cell carcinoma. Cancer 28:318–321
Wajsman Z, Beckley S, Madajewucz S, Dragone N (1980) High-dose cyclophosphamide (CPM) in metastatic renal cell cancer. Proc Am Soc Clin Oncol 21: 423, C-413
Woodruff MW, Wagle D, Gailani SD, Jones R (1967) The current status of chemotherapy for advanced renal carcinoma. J Urol 97: 611–618
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Spiers, A.S.D. (1982). Cytotoxic Drugs and Hormonal Manipulations in the Management of Carcinoma of the Kidney. In: Spiers, A.S.D. (eds) Chemotherapy and Urological Malignancy. Clinical Practice in Urology. Springer, London. https://doi.org/10.1007/978-1-4471-1332-4_2
Download citation
DOI: https://doi.org/10.1007/978-1-4471-1332-4_2
Publisher Name: Springer, London
Print ISBN: 978-1-4471-1334-8
Online ISBN: 978-1-4471-1332-4
eBook Packages: Springer Book Archive